Still outstanding: TRIUMPH-5 (head-to-head vs tirzepatide) TRIUMPH-6 (weight maintenance) and the MASH / MASLD readouts TRIUMPH-Outcomes (cardiovascular and kidney outcomes) -- a multi-year, event-driven trial Lilly said it plans to submit a Biologics License Application (BLA) for retatrutide to the FDA in the first quarter of 2027 , based on the core TRIUMPH results and supporting filings for obesity, obstructive sleep apnea, and knee osteoarthritis
Um, my first question is that it's not about just finding fat in the liver, it's about who's going to experience adverse events from it
If the Top Priority Is Convenience or Avoiding Needles Non-injectable options like sublingual or oral forms may be worth discussing with your provider
Our commitment to science-forward supplementation means we don't just follow trends
Schedule a conversation with your healthcare provider if you notice diminishing effectiveness of tirzepatide despite consistent use
[164] In March 2023, a Novo Nordisk official said, based on a randomized, double-blind study (NCT03548935 [165] ) funded by the company, that people using semaglutide to lose weight regained two-thirds of their original weight loss one year (52 weeks) after discontinuing use of the drug